Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.705 USD | -0.09% | +0.18% | -43.83% |
May. 09 | Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating | MT |
May. 09 | Morgan Stanley Upgrades Editas Medicine to Equal-Weight From Underweight | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.83% | 470M | |
+28.30% | 48.16B | |
-1.01% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+10.12% | 25.59B | |
-22.72% | 18.96B | |
+8.29% | 12.92B | |
+29.02% | 12.03B | |
-2.11% | 11.77B |
- Stock Market
- Equities
- EDIT Stock
- News Editas Medicine, Inc.
- Editas Says EDIT-103 Shows Potential in Preclinical Data for Retinitis Pigmentosa; Shares Rise